Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

Related Videos
Lisa A. Carey MD, ScM, FASCO
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Susan Domchek, MD, FASCO
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Expert on AML
Related Content

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

March 21st 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

March 21st 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

March 21st 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023